Ser715

Site Information
VRRGRsHsRtPQRRG SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 6421007
Available spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 )
Disease tissue studied:	breast cancer ( 1 ) , lung cancer ( 2 , 3 , 4 , 5 , 6 ) , non-small cell lung cancer ( 2 , 3 , 4 , 6 ) , non-small cell lung adenocarcinoma ( 2 , 3 , 4 , 5 , 6 ) , non-small cell large cell lung carcinoma ( 3 , 6 ) , non-small cell squamous cell lung carcinoma ( 5 )
Relevant cell line - cell type - tissue:	293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 8 ) , A549 (pulmonary) ( 2 ) , BT-474 (breast cell) ( 1 ) , Calu-3 (pulmonary) ( 4 ) , HCC15 (pulmonary) ( 5 ) , HCC78 (pulmonary) ( 6 ) , HCC827 (pulmonary) ( 4 ) , HeLa (cervical) ( 9 ) , HeLa S3 (cervical) ( 7 ) , LOU-NH91 (squamous) ( 5 ) , lung ( 2 , 3 , 4 , 5 , 6 ) , MCF-7 (breast cell) ( 1 ) , NCI-H1299 (pulmonary) ( 3 ) , NCI-H1355 (pulmonary) ( 2 ) , NCI-H1650 (pulmonary) ( 4 ) , NCI-H1703 (squamous) ( 5 ) , NCI-H1734 (pulmonary) ( 3 ) , NCI-H1781 (pulmonary) ( 6 ) , NCI-H1792 (pulmonary) ( 2 ) , NCI-H1944 (pulmonary) ( 3 ) , NCI-H1975 (pulmonary) ( 4 ) , NCI-H2073 (pulmonary) ( 5 ) , NCI-H2106 (pulmonary) ( 4 ) , NCI-H2228 (pulmonary) ( 6 ) , NCI-H23 (pulmonary) ( 2 ) , NCI-H2342 (pulmonary) ( 5 ) , NCI-H3122 (pulmonary) ( 6 ) , NCI-H358 (pulmonary) ( 3 ) , NCI-H441 (pulmonary) ( 2 ) , NCI-H460 (pulmonary) ( 3 ) , NCI-H661 (pulmonary) ( 6 )

Upstream Regulation
Treatments:	EGF ( 9 ) , SB202190 ( 9 )

References
1	Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290 27362937 Curated Info
2	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
3	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
4	Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
7	Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457 20860994 Curated Info
8	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
9	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info